FLUDEOXYGLUCOSE

Prostate

Small moleculeDormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 89/ 100

Competitive context

4 Active assets in the Prostate cohort.

Asset / Sponsor	Phase	Rating
Epoetin Alfa Janssen-Ortho Inc., Canada	Phase 3	B
Psma-Hbed-Cc Telix Pharmaceuticals (Innovations) Pty Limited	Phase 3	B
Casodex Memorial Sloan Kettering Cancer Center	Phase 2	B
Olaparib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	B
Gnrh Memorial Sloan Kettering Cancer Center	Phase 2	B

View all 12 →

Same molecule, other indications

FLUDEOXYGLUCOSE is also rated in:

Recurrent Adult Brain TumorDormant

BB

Indicative ·

71 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

69 / 100

prostate carcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.